APIS is committed to realise the clinical potential of systems biology and medicine in the diagnosis and personalisation of treatment, with primary focus on the development and commercialisation of molecular solutions for oncology. This includes innovative molecular tests for: breast cancer subtyping (HER2/ER/PR/Ki67), ESR1 and PIK3CA mutations detection, MET ex14 skipping and overexpression, and genotyping PGx tests.